(HealthDay News) — Vaccines to protect against respiratory syncytial virus (RSV) in newborns and older adults are being more widely accepted by the American public, while confidence in other vaccines ...

An expert panel consisting of dietitians, doctors, nutritional epidemiologists, chefs, and weight loss researchers examined ...

(HealthDay News) — Racial and ethnic disparities are seen in the use of obesity management medications, according to a study published online Dec. 17 in the Journal of Racial and Ethnic Health ...

Significant reductions seen in birth weight with exposure to certain DMTs, and increase seen in rate of small for gestational age ...

Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.

Vaccine effectiveness of 52.8% seen for ED visits, 52.3% for noncritical hospitalization, 50.4% for critical hospitalization.

Antiretroviral therapy recommended for all individuals with HIV; recommendations provided for those with specific clinical circumstances ...

The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under Priority Review for avutometinib, in combination with defactinib, for the treatment of adults with ...

The Company has been granted Competitive Generic Therapy designation, which allows for 180 days of marketing exclusivity.

The resubmitted NDA for sotagliflozin for adults with T1D and CKD included post hoc analyses from the TANDEM clinical development program and post hoc analysis from the SCORED trial.

The phase 3 STEER study enrolled 127 treatment-naïve patients aged 2 to less than 18 years with SMA type 2 who were able to sit but had never walked independently.